AkashicNET · Q004 / loving-kindness outcomes · checked 2 October 2026 · AI-executed preliminary review
Interpretation: promising evidence for a combined clinical programme; the active-control query remains unanswered. This is an initial appraisal, not a systematic review or completed risk-of-bias assessment. No canonical BQ evidence status changes.
| Study lineage | CM-OA-002 (trial) and CM-OA-003 (protocol): one study, ISRCTN97264476. Do not count as independent evidence. |
|---|---|
| Design | 48 adults with persistent depression; randomized waitlist comparison. Eight group meditation sessions followed by eight individual therapy sessions. |
| Primary finding | Clinician-rated depression (QIDS-C): reported controlled effect size d = 0.93; group-by-time p = 0.016. |
| Compassion outcome | No significant change on the Compassionate Love Scale. |
| Limits | No active treatment comparator; component effects inseparable; six-month follow-up uncontrolled. Four withdrawals per arm. Allocation known before baseline; treatment fidelity not formally tested. |
| Protocol comparison | QIDS-C primary endpoint matches. Registration retrospective. Protocol cautions that mediation analyses lack adequate power. Publication reports exploratory mediation; treat mechanism claims cautiously. |
| Reporting gap | Social-pain measure excluded after questionnaire error; other planned measures deferred. Full outcome/reporting audit remains pending. |
| Update resolved | Publisher change history: 28 February 2022, open-access funding notice. |
| Data lead | Article points to OSF erswt. Files, licence and analyses not checked here. |
AkashicNET interpretation: keep clinical depression, measured compassion, mindful awareness and metaphysical claims separate. This study supplies no direct test of consciousness surviving death or love as a cosmic property.
Next review: find an active-control study; complete protocol/registry outcome comparison; inspect effect-size uncertainty and missing-data handling. No participant data collected.
Primary sources: 2021 trial · 2020 protocol